GlassScriptPhysician profile
Ben Z Katz
NPI 1417916693
$112,985.49
in general payments reported to CMS, 2019-2025
5 companies · $12K in 2025
The $12K reported for 2025 was more than what 87% of Pediatric Infectious Diseases providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $12K · 2021: $21K · 2022: $18K · 2023: $25K · 2024: $12K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Travel and Lodging: $6,586 · Food and Beverage: $1,002 · Consulting Fee: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $20,905.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,945.00 |
| Travel and Lodging | $6,586.00 |
| Food and Beverage | $1,001.91 |
| Consulting Fee | $286.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $88,968.60 | 2019-2023 | Actimmune |
| Amgen INC. | $23,515.41 | 2024-2025 | Actimmune |
| Becton, Dickinson and Company | $286.00 | 2025 | |
| Sobi, INC | $192.87 | 2022-2023 | |
| Beta Bionics, INC. | $22.61 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.